What Happened
- India confirmed it will not sign its interim trade agreement with the United States until Washington clarifies its new tariff architecture — a position hardened after the US Supreme Court's February 20, 2026 ruling invalidated the executive branch's broad tariff-setting powers under IEEPA.
- Commerce Ministry officials indicated that the broad structure of the deal is agreed upon but that India needs to understand the precise tariff rates and their legal basis before committing to reciprocal concessions.
- India's concerns centre on two distinct fronts: the proposed 18% reciprocal tariff on Indian goods under the interim deal, and the status of existing Section 232 steel and aluminium tariffs of 25–50%.
- Non-tariff barrier discussions — covering Indian pharmaceutical pricing, data localisation requirements, and agriculture market access — remain a separate but linked negotiating track.
- The India-US trade relationship is the largest bilateral trade relationship India holds, with total merchandise trade of ~$129 billion in FY2024–25 and an Indian trade surplus of ~$45 billion.
Static Topic Bridges
Non-Tariff Barriers (NTBs) and Their Role in Modern Trade Agreements
While tariffs are the most visible trade restriction, Non-Tariff Barriers (NTBs) are increasingly the central sticking point in advanced trade negotiations. NTBs include technical barriers to trade (TBTs) — product standards, labelling, testing requirements — and sanitary and phytosanitary (SPS) measures related to food safety and animal/plant health. The WTO Agreement on Technical Barriers to Trade (TBT Agreement) and the SPS Agreement set disciplines on NTBs, requiring them to be based on international standards and not be disguised restrictions on trade. India's Quality Control Orders (QCOs) — which mandate BIS certification for imported goods — have been a US and EU concern. On the other side, India has complained about US restrictions on H-1B visas (affecting services trade) and US SPS restrictions on Indian agricultural products.
- TBT Agreement: WTO disciplines requiring NTBs to be based on international standards (ISO, Codex Alimentarius, etc.)
- SPS Agreement: Covers food safety, animal/plant health measures; requires scientific justification
- India's QCOs: Bureau of Indian Standards (BIS) mandatory certification — affects ~1,000 product categories
- H-1B visa caps: Directly affect India's services export earnings (India earns ~$250 billion in IT/services exports)
- India's pharmaceutical pricing (NPPA/DPCO) has been a persistent US Trade Representative (USTR) complaint
Connection to this news: India's insistence on clarity on tariff rates before signing reflects a broader negotiating principle: that concessions on NTBs (which India would need to offer) must be balanced against real, legally secured tariff relief — not commitments contingent on a yet-to-be-determined US tariff framework.
IEEPA and the Constitutional Limits of US Executive Trade Power
The International Emergency Economic Powers Act (IEEPA, 1977) grants the US President broad authority to regulate international commerce during a declared national emergency. Trump used IEEPA authority to impose blanket "reciprocal tariffs" on imports from most countries, including India. The US Supreme Court's February 2026 ruling held that the IEEPA-based tariff regime exceeded presidential authority — a significant constitutional check on executive trade power. This ruling created legal uncertainty about which US tariffs are now on solid statutory footing (Section 232, Section 301, and standard MFN tariffs survive; IEEPA-based reciprocal tariffs are in question). The ruling mirrors the broader "major questions doctrine" — courts requiring explicit congressional authorisation for major policy decisions with vast economic significance.
- IEEPA (1977): Authorises President to regulate foreign commerce in national emergencies; invoked for trade tariffs by Trump
- US Supreme Court ruling (Feb 20, 2026): IEEPA-based reciprocal tariffs struck down
- Section 232 (Trade Expansion Act, 1962): National security tariff authority — unaffected by the ruling
- Section 301 (Trade Act, 1974): Authorises tariffs on unfair trade practices — used against China
- Major Questions Doctrine: Courts require clear congressional authorisation for major policy shifts
Connection to this news: India's wait-and-see approach is legally prudent — committing to trade concessions anchored to a tariff framework that a US court has struck down would create an unequal bargain. India is essentially waiting for the US Congress or administration to establish a durable, legally valid tariff framework.
India's Trade Negotiation Strategy: Reciprocity and Sensitivity Lists
India's approach to trade agreements has historically been cautious, particularly regarding market access concessions on agriculture and dairy. India maintains "negative lists" (sectors excluded from liberalisation) and "sensitive lists" (sectors with slow or partial liberalisation) in all its trade agreements. The India-ASEAN FTA (2010) and India-South Korea CEPA (2010) were criticised for expanding India's trade deficit — leading to increased scepticism and more defensive negotiating postures since then. India's review of these agreements (2020–2023) and its withdrawal from RCEP (Regional Comprehensive Economic Partnership, 2019) reflect this defensive instinct. In the India-US context, India has consistently sought to protect its pharmaceutical sector (compulsory licensing rights), its public procurement preferences (Make in India), and its agricultural support programmes from US pressure.
- India withdrew from RCEP in November 2019 citing concerns about China and agriculture
- India-ASEAN FTA (2010): India's trade deficit with ASEAN grew from ~$7 billion (2010) to ~$43 billion (2022)
- Sensitive list: Products with longer tariff phase-down schedules or excluded from FTA liberalisation
- Compulsory licensing: India's right under TRIPS/Doha Declaration to issue compulsory licences for essential medicines
- Make in India: Domestic procurement preferences that the US argues disadvantage American companies
Connection to this news: India's demand for tariff clarity before signing is consistent with its established pattern of seeking "commercially meaningful" market access before offering reciprocal concessions — and its wariness of committing to US demands on NTBs and pharmaceutical pricing without guaranteed tariff relief.
Key Facts & Data
- India-US bilateral merchandise trade: ~$129 billion (FY2024–25)
- India's trade surplus with US: ~$45 billion — primary US pressure point
- Proposed reciprocal tariff on Indian goods: 18% under interim deal framework
- Section 232 tariffs: 25% steel, 25% aluminium — affecting Indian exports
- US Supreme Court ruling: February 20, 2026 — struck down IEEPA-based tariff authority
- India's $500 billion US purchase commitment (energy, aircraft, coking coal, technology) proposed over 5 years
- IEEPA (1977): US law authorising Presidential regulation of international commerce in emergencies
- India-US BTA framework first announced: February 13, 2025
- Indian pharmaceutical exports to US: ~$8–9 billion/year — protected under Indian negotiating priorities
- India withdrew from RCEP: November 2019